Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Teosyal RHA 3 is an injectable dermal filler developed by Teoxane Laboratories, composed of cross-linked hyaluronic acid (23 mg/mL) and lidocaine (0.3%). It is part of the Resilient Hyaluronic Acid (RHA) collection, which utilizes a proprietary cross-linking technology designed to preserve the natural long chains of hyaluronic acid. This formulation allows the gel to adapt to dynamic facial movements while providing structural support and volume restoration. Teosyal RHA 3 is specifically indicated for the correction of medium to deep wrinkles, such as nasolabial folds, marionette lines, and deep skin creases, as well as for lip augmentation. The product is injected into the mid-to-deep dermis and typically provides results lasting between 9 to 18 months. In the United States, the RHA collection is distributed exclusively by Revance Therapeutics and has received FDA approval for the treatment of dynamic facial wrinkles and folds.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Teosyal RHA 3.